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Abstract
Background: von Hippel-Lindau (VHL) disease is a hereditary cancer syndrome caused by germline mutations in
the VHL gene. Patients have significant morbidity and mortality secondary to vascular tumors. Disease management
is centered on tumor surveillance that allows early detection and treatment. Presymptomatic genetic testing is
therefore recommended, including in at-risk children.
Methods: We tested 17 families (n = 109 individuals) for VHL mutations including 43 children under the age of 18.
Personalized genetic counseling was provided pre and post-test and the individuals undergoing presymptomatic
testing filled out questionnaires gathering socio-demographic, psychological and psychiatric data. Mutation analysis
was performed by direct sequencing of the VHL gene. Mutation-carriers were screened for VHL disease-related
tumors and were offered follow-up annual examinations.
Results: Mutations were identified in 36 patients, 17 of whom were asymptomatic. In the initial screening, we
identified at least one tumor in five of 17 previously asymptomatic individuals. At the end of five years, only 38.9%
of the mutation-carriers continued participating in our tumor surveillance program. During this time, 14 mutation
carriers developed a total of 32 new tumors, three of whom died of complications. Gender, education, income,
marital status and religiosity were not found to be associated with adherence to the surveillance protocol. Follow-
up adherence was also independent of pre-test depression, severity of disease, or number of affected family
members. The only statistically significant predictor of adherence was being symptomatic at the time of testing
(OR = 5; 95% CI 1.2 - 20.3; p = 0.02). Pre-test anxiety was more commonly observed in patients that discontinued
follow-up (64.7% vs. 35.3%; p = 0.01).
Conclusions: The high initial uptake rate of genetic testing for VHL disease, including in minors, allowed the
discontinuation of unnecessary screening procedures in non mutation-carriers. However, mutation-carriers showed
poor adherence to long-term tumor surveillance. Therefore, many of them did not obtain the full benefit of early
detection and treatment, which is central to the reduction of morbidity and mortality in VHL disease. Studies
designed to improve adherence to vigilance protocols will be necessary to improve treatment and quality of life in
patients with hereditary cancer syndromes.
Background
von Hippel-Lindau (VHL) disease is an autosomal domi-
nant disease characterized by predisposition to multiple
tumors, which include cerebellar and spinal hemangio-
blastomas, retinal angiomas, benign renal and pancreatic
cysts, renal cell carcinoma and pheochromocytoma. The
responsible gene is VHL, a tumor suppressor located on
chromosome 3p25-26, which encodes an ubiquitin ligase
that is involved in the cellular response to hypoxia [1,2].
VHL disease affects a wide variety of organs through-
out life, and it is associated with high morbidity and
mortality. The prognosis has improved in recent years,
partly because of better surgical techniques, but primar-
ily because management of VHL disease families is now
centered on early detection and treatment of tumors
through periodic surveillance programs. Presymptomatic
genetic testing has been central to this goal. Once a cau-
sative mutation is identified in an affected family
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member, all at-risk individuals are tested and mutation
carriers undergo periodic tumor screening while non-
carriers avoid any unnecessary screening procedures [3].
Presymptomatic genetic testing is a complex process
because of the potential psychological, social and eco-
nomic implications of receiving an abnormal result, and
the difficulties associated with adapting to normal
results (survivor guilt) [4]. This is even more compli-
cated in the case of minors [5,6]. However, there is gen-
eral agreement that in the case of diseases in which the
potential benefits of early detection significantly out-
weigh the harms associated with the test, it is reasonable
to offer presymptomatic genetic testing to children
[7-9]. Examples of such diseases include multiple endo-
crine neoplasia (MEN) and familial adenomatous poly-
posis (FAP). In MEN, genetic testing is recommended
before the age of 5, given the risk of early medullary
thyroid carcinoma and the availability of prophylactic
thyroidectomy, [3,10] while in FAP, the recommended
age of genetic testing is between ages 10 and 12, when
colonoscopic or sigmoidoscopic surveillance is initiated
[11]. In both these diseases, if the mutation in the family
is known and the child is determined to be a non-car-
rier, reassurance can be given that it is safe to discon-
tinue tumor surveillance and prophylactic surgery is
thus avoided [3,10-12].
In the case of VHL disease, the tumor surveillance
program includes annual screening for central nervous
system hemangioblastomas, measurement of catechola-
mines and imaging of the abdomen, as well as semiann-
ual screening for retinal angiomas [13,14]. While the
average age of onset of VHL disease is in the third dec-
ade of life, some patients develop their first tumors
before their tenth birthday, and occasionally even in
infancy. Therefore, presymptomatic genetic testing is
justified in minors at-risk for VHL disease so that tumor
surveillance may be initiated early in mutation-carriers,
while non-carriers may avoid unnecessary screening
procedures [12,15].
We describe the uptake of diagnostic and presympto-
matic genetic testing in a series of 109 individuals for
VHL disease, the results of the initial screening for
VHL-related tumors in mutation-carriers, and the
uptake and subsequent adherence to tumor surveillance
over a five year period. An attempt was made to identify
the factors influencing their adherence to a long-term
follow-up program for hereditary cancer.
Methods
Seventeen families participated in the present study. The
proband in each family was ascertained at the National
Institute of Neurology and Neurosurgery (INNN) in
Mexico City in 2002, with a diagnosis of VHL disease or
possible VHL disease. Some of these families were
included in a previous report [16]. The diagnosis of defi-
nite VHL disease was established when the patients ful-
filled the modified clinical criteria according to
Neumann et al. [17]. Possible VHL disease was consid-
ered when the patient had a VHL disease-related tumor,
but the family history was either unclear or impossible
to corroborate. The overall scheme for genetic testing is
shown in Figure 1.
Genetic counseling was provided to each proband
after obtaining informed consent according to a proto-
col approved by the IRB at INNN. We extracted DNA
from peripheral blood samples and analyzed the coding-
sequence, promoter region and all exon-intron bound-
aries of the VHL gene for mutations, as previously
described [16]. This strategy does not detect large dele-
tions, however in our series of patients we have success-
fully identified mutations in 85-90% definite VHL
families.
When the result of the genetic test was revealed to the
proband, implications for the rest of the family were
also discussed, and genetic counseling was offered to all
relatives at risk. The initial counseling session was held
as part of a pilot VHL disease support group at INNN,
and it included details about VHL disease and its nat-
ural history, inheritance, and information about genetic
testing and tumor surveillance. A summary of the infor-
mation was provided in writing at the end of the session
and all interested individuals underwent further personal
counseling sessions with a certified medical geneticist.
Genetic testing of the family members was conducted
following the recommendations of the American Society
of Clinical Oncology for genetic testing for cancer sus-
ceptibility, [18] and according to an IRB approved pro-
tocol at INNN. All adults signed an informed consent
form for themselves and for their minor children; assent
of the child was also obtained if they were between 11
and 17 years old [7]. Pre-test counseling included inter-
views with the geneticist, social worker, and a clinical
psychologist experienced in presymptomatic genetic
testing. Adults completed a series of questionnaires: per-
sonal history and socio-demographic data, reasons for
taking the genetic test, Daily Life Inventory, Life Quality
Index, social support questionnaire, Font’s coping ques-
tionnaire, Beck’s Depression Inventory and Beck’s Anxi-
ety Inventory.
If significant distress was noted at the interview or in
the questionnaires, a further evaluation was performed
by an experienced psychiatrist and, if necessary, the test
was postponed and/or treatment for the condition was
initiated.
All mutation carriers underwent an initial screening
for VHL disease-related tumors. Appointment for the
following year’s screening was set up upon completion
of the initial screen by the social worker, and this
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procedure was repeated annually according to our
tumor surveillance program, which was adapted form
the recommended guidelines of the VHL family alliance,
[13,14,19] and is shown in Table 1.
Crude and adjusted odds ratios (ORs) were estimated
by logistic regression models. Tests for adherence to
surveillance protocol variables and statistical significance
were evaluated using two-sided design-based tests at the
0.05 level of significance. Analysis was done using
STATA Intercooled version 10.1 (StataCorp. Stata Sta-
tistical Software: Release 10. 2007;10.1)
Results
Uptake of presymptomatic testing
Our genetic testing program for VHL disease included 17
families, ten of which had definite VHL disease and seven
had possible VHL disease. Testing of the proband in each
family allowed us to identify mutations in the VHL gene in
9/10 definite VHL disease families and 3/7 possible VHL
disease families. It is possible that the family diagnosed
with definite VHL disease in which we did not identify a
mutation has a large gene deletion, which would have
been missed by our current testing strategy[16].
Figure 1 Scheme for genetic counseling and testing in our cohort of families with VHL disease.
Table 1 Tumor surveillance program in VHL gene mutation-carriers
Age (y) Physical exam Fundoscopic examination Urinary catecholamines Brain/spinal imaging Abdominal imaging
0 - 2 12 mo 24 mo ———— ———— ———
2-10 12 mo 12 mo 12 mo 12 mo ———
11-19 12 mo 6 mo 12 mo 12 mo 12 mo (US)
>20 12 mo 6 mo 12 mo 12 mo 12 mo (MRI)
Mo: months; US: Ultrasonographic screening; MRI: Magnetic resonance imaging
Adapted from: VHL family alliance http://www.vhl.org/handbook/vhlhb4.php#Suggested,
Choyke et al, 1995 and Lonser et al, 2003.
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A detailed overview of the uptake of presymptomatic
testing in our cohort is outlined in Figure 2. Analysis of
the pedigrees of the 12 families with known mutations
revealed that there were 157 family members at 25 -
50% risk; 92 of them underwent genetic testing. In 85
cases, the testing was presymptomatic because the indi-
viduals were asymptomatic; the remaining seven already
had some manifestation of VHL disease and received
confirmatory diagnostic testing. Almost half of the at-
risk family members tested were children under the age
of 18 (43/92, 47%).
Uptake of the test was high and we did not experience
any drop-out prior to the delivery of the genetic test
results. Indeed, all of the 92 family members that
attended personal counseling sessions consented to
genetic testing. However, at-risk family members that
only received information through their affected rela-
tives, and who did not come to the information and
counseling sessions, did not express any further interest
in genetic testing or periodic clinical surveillance (n =
65; 41%).
The genetic testing results revealed a total of 36 muta-
tion carriers, with a median age of 20.5 years (range 1 -
45 years; SD ± 11.41 years). They were 12 probands and
24 at-risk family members, 17 of whom were asympto-
matic at the time of testing (Table 2).
Genotype-phenotype analysis confirmed that families
carrying protein truncating mutations had a VHL dis-
ease type 1 phenotype, and families with missense muta-
tions had VHL disease with pheochromocytoma (VHL
type 2). The exception was family 19 (P86S missense
mutation) in which the only affected individual died
without evidence of pheochromocytoma.
Tumor surveillance and follow-up
After disclosure of the test results, the mutation carriers
were offered screening for VHL disease related tumors
and follow-up with annual examinations. All of them (n
= 36) undertook the initial screening, in which we iden-
tified one or more VHL disease tumors in 5/17 pre-
viously asymptomatic mutation carriers (Table 2).
Five years after the 36 mutation-carriers underwent
the initial tumor screening, only 14 (38.9%; from eight
families) continued with annual surveillance. Since the
time of genetic testing, 14 mutation-carriers have devel-
oped a total of 32 new VHL disease-related tumors
(Table 2). One child died of complications of an inoper-
able bulbar hemangioblastoma and two adults died of
complications of metastatic renal cancer. Individuals in
Figure 2 Uptake of predictive testing in our cohort of 17 families with VHL disease.
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whom more than one tumor was identified during the
follow-up period were almost twice as likely to die com-
pared to those who did not develop further tumors (OR
= 1.8; 95% CI = 1.1 - 3.1; p = 0.03).
In order to identify factors that may have influenced
the uptake and adherence to the tumor surveillance pro-
gram, we analyzed the clinical (Table 3), psychological
and socio-demographic features (Table 4) of the muta-
tion carriers. Whereas clinical information was available
for all 36 patients, the complete set of socio-
demographic and psychological tests was available for
17 adults and may represent a limitation of the study.
Individuals who were symptomatic before the molecu-
lar test were 5 times more likely to continue the surveil-
lance program (OR = 5; 95% CI 1.2 - 20.3; p = 0.02),
which was maintained even after adjustment for the
clustering of observations (OR = 5.0, CI 95%= 1.37-
18.29; p = 0.02). On the other hand, significant pre-test
anxiety was more common amongst the individuals that
prematurely dropped out of surveillance (64.7% vs.
Table 2 Results of genetic testing and tumor surveillance in VHL gene mutation-carriers
Family Mutation Age Follow-up Status pre-test Status 1st. Screening Final status§
1 p.F76del >18 Y Affected 3 Hb, KC + PC
>18 Y Affected 3 Hb Same
>18 Y Affected 4 Hb Same
<18 Y Asymptomatic Asymptomatic Asymptomatic
6 c.99_100InsA* >18 Y Affected 1 Hb, Bilat RA Same
<18 N Affected 4 Hb, Bilat RA, KC, PC + 1 Hb, ✞
>18 N Affected 1 Hb, Bilat RA, KC, PC + 2 RCC
>18 N Asymptomatic 1 Hb + 1 Hb
<18 N Asymptomatic Asymptomatic Asymptomatic
<18 N Asymptomatic Asymptomatic Asymptomatic
7 c.99_100InsA* >18 N Asymptomatic EC Same
<18 N Asymptomatic Asymptomatic Asymptomatic
>18 N Affected 1 Hb, 1 RCC, KC, PC + 1 RCC
<18 N Asymptomatic Asymptomatic + 1 Hb
>18 N Asymptomatic 3 Hb, KC, PC + 1 RCC
<18 N Asymptomatic Asymptomatic Asymptomatic
>18 N Asymptomatic 1 Hb, KC, PC Same
>18 N Affected 1 Hb + 1 Hb
<18 Y Affected 1 Hb Same
<18 N Asymptomatic Asymptomatic Asymptomatic
>18 N Asymptomatic 1 Hb + KC, PC, 1 RCC
>18 N Affected 1 Hb, KC, PC Same
<18 N Asymptomatic Asymptomatic Asymptomatic
12 p.D121G >18 Y Affected 2 Hb, Bilat RA, KC, PC, 1 RCC, 1 pheo Same
16 p.R161X >18 N Affected 3 Hb, KC, PC Same
19 p.P86S >18 N Affected 1 Hb, KC, PC, 1 RCC + 1RCC, 1 Hb, ELST, ✞
20 p.C162F >18 Y Affected 2 Hb, Unilat RA, KC, PC, 1 pheo + 1 RCC, 1 pheo
21 p.R82P >18 Y Affected 1 Hb + 2 Hb, Bilat RA, KC, PC, 1 RCC, ✞
22 c.56_57DupInv CGGGAGGC* >18 N Affected 1 Hb Same
>18 N Asymptomatic Asymptomatic Asymptomatic
>18 N Asymptomatic Asymptomatic Asymptomatic
23 p.E134X* >18 Y Affected 2 Hb, Bilat RA, KC, 1 RCC Same
>18 Y Asymptomatic Asymptomatic Asymptomatic
>18 Y Asymptomatic Asymptomatic Asymptomatic
43 p.P86S >18 Y Affected 1 Hb + 3 Hb, 2 RCC, PCA, 1 Pheo
53 p.L89P >18 Y Affected KC, PC + 1 Hb
* Novel mutation. Y = Yes, N = No; Hb = Hemangioblastoma, KC = Kidney cysts, PC = Pancreatic cysts, EC = Epididymal cysts, RCC = Renal cell carcinoma, Pheo
= Pheochromocytoma, ELST = Endolymphatic sac tumor, PCA = Pancreatic cancer. ✞ Deceased. §Final status was determined by the results of the most recent
surveillance testing or, if the patient had discontinued surveillance final status was determined by phone re-contact or if the patient returned seeking medical
attention for new symptoms.
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35.3%; p = 0.01). Follow-up was not found to be asso-
ciated with having or not having children, the mutation
status or affectedness of the children, and there was
also no relationship with pre-test depression (Table 3).
Gender, education, income, marital status, and religios-
ity, did not modify the likelihood of continuing
the tumor surveillance beyond the initial screening
(Table 4).
In the single mutation-free family with definite VHL
disease based on clinical criteria we suggested that the
proband and family members at 50% risk continue with
the annual tumor screening. We also suggested long-
term surveillance for the probands of the possible VHL
disease families.
Discussion
We describe the five-year follow-up of a series of 109
individuals that underwent presymptomatic genetic test-
ing for VHL disease. We identified a total of 36 mutation
carriers, of which 17 were asymptomatic at the time of
testing. Initial screening for tumors revealed that five pre-
sumptive asymptomatic individuals already had one or
more VHL disease-related tumor(s) and a total of 32 new
tumors were identified during the five-year follow-up.
There are few reports of long-term follow-up of indi-
viduals that have been tested for hereditary cancer syn-
dromes, and very little is known about the uptake and
adherence to follow-up in VHL disease. Further analyses
of long-term outcomes are necessary, given the general-
ized assumption amongst specialists providing genetic
testing that communication of cancer risk information
leads to a subsequent modification in behavior [20].
Recently, Beery et al made a systematic review of
Table 3 Clinical correlates of adherence to tumor surveillance program
Clinical features n Follow-up (+) Follow-up (-) p
Gender 36 n.s.
Male 13 5 8
Female 23 9 14
Pre-test clinical status 36 p = 0.02
Asymptomatic 3 14
Symptomatic 11 8
Pre-test depression† 17 n.s.
Yes 1 3
No 6 7




One or more children 7 9
No children 7 13
Clinical status of offspring†‡ 16 n.s.
Affected 2 3
Unaffected 5 6
Mutation status of offspring†‡ 16 n.s.
Mutation-carrier 5 6
Non mutation-carrier 2 3
Follow-up (+): Patients that continued in the tumor surveillance program five years after genetic testing. Follow-up (-): Patients that had abandoned the tumor
surveillance program five years after genetic testing.
† Score ≥ 10 on Beck’s Depression Inventory. Includes individuals that completed the psychological questionnaires (n = 17)
‡ Score ≥ 8 on Beck’s Anxiety Inventory. Includes individuals that completed the psychological questionnaires (n = 17)
†‡ Includes mutation-carriers who had children (n = 16)
Table 4 Socio-demographic correlates of adherence to
tumor surveillance program
Sociodemographic feature n Follow-up (+) Follow-up (-) p
Religious n.s.
No 10 4 6
Yes 7 3 4
Education n.s.
< National average 7 3 4
≥ National average 10 4 6
Marital Status n.s.
Married† 10 4 6
Not married‡ 7 3 4
Income n.s.
< National poverty line 13 5 8
≥ National poverty line 4 2 2
† Includes married, civil unions and cohabitation
‡ Includes single, divorced and widowed
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published studies describing the health-promotion and
risk-reduction behavioral outcomes following presymp-
tomatic genetic testing in adult-onset disorders [21].
However, their analysis included short-term follow-up
for only two hereditary cancer syndromes: hereditary
breast and ovarian cancer syndrome (HBOC) and her-
editary non-polyposis colon cancer (HNPCC) [21,22].
One report of families with VHL disease and other
inherited cancer predisposing syndromes showed that
the uptake of presymptomatic testing for VHL disease
was 70% of the at-risk family members; however, the
adherence of mutation-carriers to long term surveillance
program was not reported [23].
In our series of VHL disease families, initial interest
and uptake of presymptomatic genetic testing for VHL
disease was very high, but less than half of the mutation
carriers engaged in risk-reduction behaviors through the
five year follow-up period. Whenever a patient was diag-
nosed with VHL disease, genetic counseling was pro-
vided to explain the risks for the rest of the family
members. Once a VHL disease-causing mutation was
identified, we contacted the patient again and stressed
the importance of sharing this information with their
relatives. We organized informative sessions for
extended VHL disease families, and personal genetic
counseling for all relatives at risk. All of the at-risk rela-
tives that attended these sessions chose to be tested for
VHL mutations and to have their children tested as well.
This is different from what was observed in patients at
the same hospital who were offered presymptomatic
genetic testing for Huntington disease. In a series of 373
families with Huntington disease followed over 14 years
at the INNN, only 11.5% had one or more individuals
that underwent presymptomatic testing, in contrast with
58% of the at-risk VHL disease family members (p <
0.001). This difference in uptake of presymptomatic
genetic testing is most likely attributable to the lack of
preventive and therapeutic options available in Hunting-
ton disease [24,25].
A relevant factor in determining uptake of genetic
testing was whether they had personal genetic counsel-
ing. When at-risk family members were only informed
about the possibility of testing through a relative and/or
written material, they were unlikely to pursue further
counseling or testing. This differs from what has been
reported in other populations, where at-risk family
members contacted through telephone interviews or let-
ters had a positive attitude and high uptake rate of
genetic testing [23,26,27].
The poor adherence to long-term surveillance also
contrasts with the observations of another series of
Mexican patients with hereditary cancer syndromes
(HBOC or HNPCC) enrolled in a similar surveillance
program at the Instituto Nacional de Cancerologia in
Mexico City, Mexico. In that cohort, >95% of patients
with HBOC or HNPCC have continued with long-term
follow-up (Dr. Silvia Vidal, personal communication),
ruling out population-specific causes for the drop-out in
VHL disease surveillance.
Forty-three of the tested individuals were children
under the age of 18. In general terms, it has been sug-
gested that presymptomatic genetic testing should not
be undertaken for children unless the benefits outweigh
potential harm [7,9]. In the case of VHL disease, as well
as multiple endocrine neoplasia syndromes and familial
adenomatous polyposis, it is considered justifiable to
perform presymptomatic testing of minors based on the
early age of onset of some of the tumors, the potential
of reducing morbidity by early treatment, and to prevent
non-carriers from undergoing expensive and invasive
annual screening [8,11,12]. In our series, of the children
that were mutation carriers (n = 10), three had tumors
and one died of complications of a recurrent bulbar
hemangioblastoma. On the other hand, 33 at-risk chil-
dren were found to not carry the mutation and were
therefore relieved from the burden of life-long screening
for VHL disease-related tumors.
We encouraged continued surveillance for families in
whom we were unable to identify VHL mutations. This
recommendation was based on literature reports that
have calculated that patients with an apparently isolated
VHL-related tumor and no detectable VHL mutation
have a risk of ≈ 5% of developing subsequent VHL-
related tumors within 10 years of the diagnosis of their
first tumor [28]. Interestingly, the adherence to follow-
up surveillance was lower in the families with confirmed
VHL mutations (38.9%) than in families with definite or
possible VHL disease in whom no mutation was identi-
fied (63.5%; p = 0.01). They include the proband of the
definite VHL disease family and her three daughters,
one of which has since developed a cerebellar heman-
gioblastoma. Although the reason for this difference is
unknown, one may speculate that the uncertainty of
knowing their carrier-status may have prompted them
to stay in the surveillance program; it would be interest-
ing to design a future study to address this issue.
Most socio-demographic and psychiatric variables ana-
lyzed did not correlate with follow-up adherence. How-
ever, individuals who were already symptomatic at the
time of testing had a higher likelihood of adhering to
long-term follow-up (OR = 5; 95% CI 1.2 - 20.3; p =
0.02), and those who had significant pre-test anxiety
tended to abandon the follow-up program (p = 0.01).
Interestingly, in the case of families with several muta-
tion-carriers, most of the family members tended to
take the same stance towards long-term surveillance.
Families 1 and 23 had all their mutation-carriers con-
tinue with the follow-up program five years after testing,
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while Families 6, 7 and 22 did not continue (with the
exception of one adult in Family 6 and one child in
Family 7). This is in contrast with a previous study of
VHL disease in which attitudes towards genetic testing
for VHL disease in the patient and offspring were perso-
nal decisions and not those of a group [29].
Another factor that seemingly promoted active partici-
pation in follow-up testing was if the family leader, i.e.,
the person encouraging family members to attend, and
often also the person that coordinated appointments at
the hospital, was a female. Unfortunately, the small
number of families with male leaders did not allow sta-
tistical confirmation of this trend. One family (Family 7)
further helped to support this notion: at the beginning
of the program, the wife of a proband actively promoted
education and participation of all family members in the
VHL disease program. However, after her death the
family was lost to follow-up and several attempts to
contact them were not effective in bringing them back
into the program. These findings are consistent with
previous analyses of psycho-social factors influencing
genetic testing, which have suggested that families led
by a matriarch have higher levels of participation and
follow-up than families led by a patriarch. It has also
been suggested that engaging a matriarch in the process
of risk communication and management may improve
overall uptake [30,31].
Finally, we considered the economic burden of the
surveillance program, which includes multiple medical
procedures, some of them potentially costly, as an impe-
diment for continued surveillance. However, subjects
enrolled in our VHL disease screening program at
INNN were specifically exempt from ≥ 90% of the costs
of all the screening tests, thus eliminating financial con-
straints as a cause for leaving the program. Indeed, we
also scheduled and synchronized all tests to be per-
formed during a single hospital visit, and offered conve-
nient re-scheduling, when needed. Another potential
explanation for the lack of adherence to long-term fol-
low-up is that patients report being overwhelmed by the
disease which, in contrast to other hereditary cancer
syndromes, has an early onset and affects a wide variety
of organs. However, our analysis did not reveal a differ-
ence in adherence to surveillance in patients with more
severe disease (measured as number of tumors) and
continuation in the surveillance program. This is a little
explored aspect of genetic testing for hereditary cancer,
and warrants further analysis.
Conclusions
The high initial uptake rate of genetic testing for VHL
disease, including in minors, allowed the discontinuation
of unnecessary screening procedures in non mutation-
carriers. However, mutation-carriers showed poor adher-
ence to long-term tumor surveillance. Therefore, many
of them did not obtain the full benefit of early detection
and treatment, which is central to the reduction of mor-
bidity and mortality in VHL disease. The factors that
influence the uptake of risk-reducing and health-pro-
moting behaviors need to be analyzed in larger, prospec-
tive follow-up series, in order to determine how to
realize the potential benefits of presymptomatic genetic
testing and systematic tumor surveillance.
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